Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer
Background About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which...
Saved in:
| Published in | Cancer cell international Vol. 24; no. 1; pp. 56 - 17 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
05.02.2024
BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2867 1475-2867 |
| DOI | 10.1186/s12935-024-03231-6 |
Cover
| Abstract | Background
About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.
Methods
H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.
Results
H19 silencing in both PC-3 and 22Rv1 cells increased:
i
) E-cadherin and β4 integrin expression as well as proliferation and invasion,
ii
) in vivo tumor growth, and
iii
) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.
Conclusions
Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy. |
|---|---|
| AbstractList | BackgroundAbout 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.MethodsH19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.ResultsH19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.ConclusionsOur findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy. About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models. H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects. H19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs. Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy. Abstract Background About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models. Methods H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects. Results H19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs. Conclusions Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy. About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.BACKGROUNDAbout 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.METHODSH19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.H19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.RESULTSH19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy.CONCLUSIONSOur findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy. Background About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models. Methods H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects. Results H19 silencing in both PC-3 and 22Rv1 cells increased: i ) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii ) in vivo tumor growth, and iii ) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs. Conclusions Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy. |
| ArticleNumber | 56 |
| Author | De Martino, Sara Gaetano, Carlo Porru, Manuela Farsetti, Antonella Troisi, Fabiola Grassi, Claudio Ripoli, Cristian Carlino, Angela Rotili, Dante Nanni, Simona Fiorentino, Vincenzo Bassi, Pier Francesco Pontecorvi, Alfredo Strigari, Lidia Pecci, Valeria Pinto, Francesco Aiello, Aurora Pierconti, Francesco Mai, Antonello Martini, Maurizio |
| Author_xml | – sequence: 1 givenname: Valeria surname: Pecci fullname: Pecci, Valeria organization: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore – sequence: 2 givenname: Fabiola surname: Troisi fullname: Troisi, Fabiola organization: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore – sequence: 3 givenname: Aurora surname: Aiello fullname: Aiello, Aurora organization: National Research Council (CNR)-IASI – sequence: 4 givenname: Sara surname: De Martino fullname: De Martino, Sara organization: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, National Research Council (CNR)-IASI – sequence: 5 givenname: Angela surname: Carlino fullname: Carlino, Angela organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS” – sequence: 6 givenname: Vincenzo surname: Fiorentino fullname: Fiorentino, Vincenzo organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS”, Department of Woman, Child and Public Health, Università Cattolica del Sacro Cuore – sequence: 7 givenname: Cristian surname: Ripoli fullname: Ripoli, Cristian organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS”, Department of Neuroscience, Università Cattolica del Sacro Cuore – sequence: 8 givenname: Dante surname: Rotili fullname: Rotili, Dante organization: Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma – sequence: 9 givenname: Francesco surname: Pierconti fullname: Pierconti, Francesco organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS”, Department of Woman, Child and Public Health, Università Cattolica del Sacro Cuore – sequence: 10 givenname: Maurizio surname: Martini fullname: Martini, Maurizio organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS”, Department of Woman, Child and Public Health, Università Cattolica del Sacro Cuore – sequence: 11 givenname: Manuela surname: Porru fullname: Porru, Manuela organization: Translational Oncology Research Unit, IRCCS- Regina Elena National Cancer Institute – sequence: 12 givenname: Francesco surname: Pinto fullname: Pinto, Francesco organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS” – sequence: 13 givenname: Antonello surname: Mai fullname: Mai, Antonello organization: Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma – sequence: 14 givenname: Pier Francesco surname: Bassi fullname: Bassi, Pier Francesco organization: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Fondazione “Policlinico Universitario A. Gemelli IRCCS” – sequence: 15 givenname: Claudio surname: Grassi fullname: Grassi, Claudio organization: Fondazione “Policlinico Universitario A. Gemelli IRCCS”, Department of Neuroscience, Università Cattolica del Sacro Cuore – sequence: 16 givenname: Carlo surname: Gaetano fullname: Gaetano, Carlo organization: Laboratory of Epigenetics, Istituti Clinici Scientifici Maugeri IRCCS – sequence: 17 givenname: Alfredo surname: Pontecorvi fullname: Pontecorvi, Alfredo organization: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Fondazione “Policlinico Universitario A. Gemelli IRCCS” – sequence: 18 givenname: Lidia surname: Strigari fullname: Strigari, Lidia organization: Department of Medical Physics, S. Orsola, Malpighi University Hospital – sequence: 19 givenname: Antonella surname: Farsetti fullname: Farsetti, Antonella email: antonella.farsetti@cnr.it organization: National Research Council (CNR)-IASI – sequence: 20 givenname: Simona surname: Nanni fullname: Nanni, Simona email: simona.nanni@unicatt.it organization: Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Fondazione “Policlinico Universitario A. Gemelli IRCCS” |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38317193$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAUjFARbRf-AAdkiQuXUH8nPiFUQVuoxIFythznOetV1l7spGj_PcmmlLaHnvzxZsbznue0OAoxQFG8JfgjIbU8y4QqJkpMeYkZZaSUL4oTwitR0lpWRw_2x8VpzhuMSVVL_Ko4ZjUjFVHspPhzY1IHgw8dig5dEnVmoe-RadeQfQxoG3uwYw8ZWZ_s6Ie0R80eXfz8Xn7jCHa-TWOHfFj7xg8ZbWEweTCDt2iXYpcgH1R8mI9zAZA1wUJ6Xbx0ps_w5m5dFb--frk5vyyvf1xcnX--Lq3kdCib1hnXNGCd4UbUnEohlRNEOQeyBje1w4mUglTYUgets9IK3ELlqKoExWxVXC26bTQbvUt-a9JeR-P14SKmTps02e1BU3CyYUaoStZcAG2sJLxWtXJMGTKNbFV8WrR2Y7OF1kIYkukfiT6uBL_WXbzVBE-ClZSTwoc7hRR_j5AHvfV5HrgJEMesqaJU8YoxNUHfP4Fu4pjCNKsZJSTDis-W3j20dO_l3wdPALoA7DT_nMDdQwjWc4r0kiI9pUgfUqRnm_UTkvXzp8a5Ld8_T2ULNU_vhA7Sf9vPsP4CD5Pc3w |
| CitedBy_id | crossref_primary_10_3390_biomedicines12102322 crossref_primary_10_12998_wjcc_v12_i27_6070 crossref_primary_10_1007_s11596_024_2949_0 |
| Cites_doi | 10.18632/oncotarget.19100 10.1016/j.eururo.2019.08.005 10.1016/j.ejphar.2018.08.021 10.1101/gad.315739.118 10.1038/srep38414 10.1101/cshperspect.a033688 10.1007/s12020-020-02508-w 10.18632/oncotarget.25182 10.1038/nature11262 10.1038/s41388-022-02190-4 10.1007/s12094-022-02779-x 10.1101/gad.276790.115 10.1038/sj.bjc.6604242 10.1038/s41467-021-26901-9 10.1016/j.canlet.2013.01.033 10.1016/j.molcel.2022.05.027 10.1073/pnas.0907676107 10.3390/cancers14122902 10.1007/s11033-020-05695-x 10.1038/351153a0 10.1007/s12032-014-0914-7 10.1038/onc.2011.114 10.3390/ijms20164012 10.1007/s10585-006-9011-4 10.3389/fonc.2022.877379 10.4103/ijmr.IJMR_1409_18 10.1242/dev.113.4.1105 10.21873/cgp.20324 10.14639/0392-100X-N1527 10.1016/j.biopha.2019.109384 10.1038/s41571-019-0284-3 10.1016/j.celrep.2017.09.078 10.1016/j.eururo.2021.03.005 10.1111/j.1464-410X.2006.06663.x 10.1007/s13277-013-1083-6 10.1002/advs.202101895 10.18632/oncotarget.24496 10.1007/s12032-016-0734-z 10.3390/ijms22020968 10.1001/jama.294.4.433 10.3322/caac.21660 10.1038/s41419-020-03354-4 10.3390/cancers13010015 10.1002/pros.22742 10.21037/tau-20-1118 10.1007/s100380050036 10.1186/s13148-016-0264-8 10.1016/j.canlet.2020.11.006 10.4103/UA.UA_47_20 10.1111/febs.12902 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7TM 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12935-024-03231-6 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1475-2867 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_2ef6b3a5976845e2bc6148989f39a138 PMC10845766 38317193 10_1186_s12935_024_03231_6 |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Ministero della Salute grantid: RF-2019-12370266 funderid: http://dx.doi.org/10.13039/501100003196 – fundername: Regione Lazio grantid: project ID A0375-2020-36597 funderid: http://dx.doi.org/10.13039/501100009880 – fundername: EU-CardioRNA COST Action grantid: CA17129 – fundername: Ministero dell’Istruzione, dell’Università e della Ricerca grantid: PRIN2017S55RXB funderid: http://dx.doi.org/10.13039/501100003407 – fundername: Regione Lombardia grantid: progetto “Immunhub” funderid: http://dx.doi.org/10.13039/501100009882 – fundername: Ricerca Corrente grantid: Progetto di Rete Aging “Promising” Ricerca Corrente 2021 – fundername: Ministero dell’Università e della Ricerca grantid: FISR2019_00374 funderid: http://dx.doi.org/10.13039/501100021856 – fundername: Fondazione AIRC per la ricerca sul cancro ETS grantid: AIRC under IG 2019-ID 22858 project—PI Nanni Simona funderid: http://dx.doi.org/10.13039/100020581 – fundername: Ministero della Salute grantid: RF-2019-12370266 – fundername: Regione Lazio grantid: project ID A0375-2020-36597 – fundername: Fondazione AIRC per la ricerca sul cancro ETS grantid: AIRC under IG 2019-ID 22858 project-PI Nanni Simona – fundername: Ministero dell'Università e della Ricerca grantid: FISR2019_00374 – fundername: Regione Lombardia grantid: progetto "Immunhub" – fundername: Ministero dell'Istruzione, dell'Università e della Ricerca grantid: PRIN2017S55RXB – fundername: Ricerca Corrente grantid: Progetto di Rete Aging "Promising" Ricerca Corrente 2021 |
| GroupedDBID | --- 0R~ 29B 2WC 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR ISR ITC KQ8 LGEZI LOTEE M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M AAYXX ALIPV CITATION NPM 3V. 7TM 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c642t-bdfafbbecfa4a58426569f519ffe68ef86041665170c2fedfc6c50de7f2975203 |
| IEDL.DBID | M48 |
| ISSN | 1475-2867 |
| IngestDate | Wed Aug 27 01:32:02 EDT 2025 Thu Aug 21 18:35:30 EDT 2025 Thu Sep 04 20:33:59 EDT 2025 Mon Jun 30 15:00:01 EDT 2025 Thu Apr 03 07:06:48 EDT 2025 Tue Jul 01 02:41:58 EDT 2025 Thu Apr 24 23:10:06 EDT 2025 Sat Sep 06 07:29:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | lncRNA Metastasis Lysine demethylase Preclinical models |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c642t-bdfafbbecfa4a58426569f519ffe68ef86041665170c2fedfc6c50de7f2975203 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/2ef6b3a5976845e2bc6148989f39a138 |
| PMID | 38317193 |
| PQID | 2925630948 |
| PQPubID | 42567 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2ef6b3a5976845e2bc6148989f39a138 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10845766 proquest_miscellaneous_2922947339 proquest_journals_2925630948 pubmed_primary_38317193 crossref_primary_10_1186_s12935_024_03231_6 crossref_citationtrail_10_1186_s12935_024_03231_6 springer_journals_10_1186_s12935_024_03231_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-05 |
| PublicationDateYYYYMMDD | 2024-02-05 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Cancer cell international |
| PublicationTitleAbbrev | Cancer Cell Int |
| PublicationTitleAlternate | Cancer Cell Int |
| PublicationYear | 2024 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | NK Sedky (3231_CR32) 2022; 24 D Pouessel (3231_CR7) 2007; 99 F Poirier (3231_CR18) 1991; 113 T Sohda (3231_CR20) 1998; 43 H Wang (3231_CR10) 2014; 35 M Daher (3231_CR4) 2021; 13 M Zhu (3231_CR28) 2014; 281 3231_CR25 C Possieri (3231_CR42) 2021; 72 V Vaira (3231_CR47) 2010; 107 A Sanchez (3231_CR50) 2022; 19 G Wang (3231_CR12) 2018; 32 CR Jeter (3231_CR16) 2011; 30 G Gandaglia (3231_CR6) 2014; 74 M Luo (3231_CR21) 2013; 333 S De Martino (3231_CR44) 2022; 14 AB Herman (3231_CR14) 2022; 82 L Zha (3231_CR52) 2016; 33 EM Hurt (3231_CR15) 2008; 98 L Bacci (3231_CR24) 2019; 20 B Fazi (3231_CR23) 2018; 9 Z Cao (3231_CR40) 2021; 12 MS Bartolomei (3231_CR17) 1991; 351 H Sung (3231_CR1) 2021; 71 B Lu (3231_CR51) 2021; 8 A Benyoucef (3231_CR45) 2016; 30 VM Morozov (3231_CR37) 2017; 8 3231_CR46 N Singh (3231_CR27) 2021; 12 L Kruidenier (3231_CR36) 2012; 488 S Biswas (3231_CR33) 2018; 837 X Yin (3231_CR34) 2019; 118 MJ Connor (3231_CR8) 2020; 17 EB Zhang (3231_CR19) 2014; 31 A Kumaraswamy (3231_CR30) 2021; 80 MB Culp (3231_CR2) 2020; 77 3231_CR3 A Aiello (3231_CR43) 2016; 6 3231_CR5 WL Harryman (3231_CR29) 2016; 1866 M Flum (3231_CR48) 2022; 41 JM Drake (3231_CR41) 2005; 22 A Sanchez (3231_CR35) 2021; 22 3231_CR38 T Ezponda (3231_CR53) 2017; 21 C Hillyar (3231_CR31) 2020; 12 S Ong (3231_CR9) 2021; 10 F Moreira-Silva (3231_CR11) 2022; 12 B Alipoor (3231_CR22) 2020; 47 I Graça (3231_CR13) 2016; 8 N Goyal (3231_CR49) 2021; 153 YW Shermane Lim (3231_CR26) 2021; 500 A Sanchez (3231_CR39) 2020; 24 |
| References_xml | – volume: 8 start-page: 62131 issue: 37 year: 2017 ident: 3231_CR37 publication-title: Oncotarget doi: 10.18632/oncotarget.19100 – volume: 77 start-page: 38 issue: 1 year: 2020 ident: 3231_CR2 publication-title: Eur Urol doi: 10.1016/j.eururo.2019.08.005 – volume: 837 start-page: 8 year: 2018 ident: 3231_CR33 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2018.08.021 – volume: 32 start-page: 1105 issue: 17–18 year: 2018 ident: 3231_CR12 publication-title: Genes Dev doi: 10.1101/gad.315739.118 – volume: 6 start-page: 38414 year: 2016 ident: 3231_CR43 publication-title: Sci Rep doi: 10.1038/srep38414 – ident: 3231_CR5 doi: 10.1101/cshperspect.a033688 – volume: 72 start-page: 711 issue: 3 year: 2021 ident: 3231_CR42 publication-title: Endocrine doi: 10.1007/s12020-020-02508-w – ident: 3231_CR38 doi: 10.18632/oncotarget.25182 – volume: 488 start-page: 404 issue: 7411 year: 2012 ident: 3231_CR36 publication-title: Nature doi: 10.1038/nature11262 – volume: 41 start-page: 1492 issue: 10 year: 2022 ident: 3231_CR48 publication-title: Oncogene doi: 10.1038/s41388-022-02190-4 – volume: 12 start-page: e11725 issue: 11 year: 2020 ident: 3231_CR31 publication-title: Cureus 27 – volume: 24 start-page: 1262 issue: 7 year: 2022 ident: 3231_CR32 publication-title: Clin Transl Oncol doi: 10.1007/s12094-022-02779-x – volume: 30 start-page: 508 issue: 5 year: 2016 ident: 3231_CR45 publication-title: Genes Dev doi: 10.1101/gad.276790.115 – volume: 98 start-page: 756 issue: 4 year: 2008 ident: 3231_CR15 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604242 – volume: 12 start-page: 7349 issue: 1 year: 2021 ident: 3231_CR27 publication-title: Nat Commun doi: 10.1038/s41467-021-26901-9 – volume: 333 start-page: 213 issue: 2 year: 2013 ident: 3231_CR21 publication-title: Cancer Lett doi: 10.1016/j.canlet.2013.01.033 – volume: 82 start-page: 2252 issue: 12 year: 2022 ident: 3231_CR14 publication-title: Mol Cell doi: 10.1016/j.molcel.2022.05.027 – volume: 107 start-page: 8352 issue: 18 year: 2010 ident: 3231_CR47 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0907676107 – volume: 14 start-page: 2902 issue: 12 year: 2022 ident: 3231_CR44 publication-title: Cancers doi: 10.3390/cancers14122902 – volume: 47 start-page: 6357 issue: 8 year: 2020 ident: 3231_CR22 publication-title: Mol Biol Rep Agosto doi: 10.1007/s11033-020-05695-x – volume: 351 start-page: 153 issue: 6322 year: 1991 ident: 3231_CR17 publication-title: Nature doi: 10.1038/351153a0 – volume: 31 start-page: 914 issue: 5 year: 2014 ident: 3231_CR19 publication-title: Med Oncol doi: 10.1007/s12032-014-0914-7 – volume: 30 start-page: 3833 issue: 36 year: 2011 ident: 3231_CR16 publication-title: Oncogene doi: 10.1038/onc.2011.114 – volume: 20 start-page: E4012 issue: 16 year: 2019 ident: 3231_CR24 publication-title: Int J Mol Sci doi: 10.3390/ijms20164012 – volume: 1866 start-page: 221 issue: 2 year: 2016 ident: 3231_CR29 publication-title: Biochim Biophys Acta – volume: 22 start-page: 674 issue: 8 year: 2005 ident: 3231_CR41 publication-title: Clin Exp Metastasis doi: 10.1007/s10585-006-9011-4 – volume: 12 start-page: 877379 year: 2022 ident: 3231_CR11 publication-title: Front Oncol doi: 10.3389/fonc.2022.877379 – volume: 153 start-page: 484 issue: 4 year: 2021 ident: 3231_CR49 publication-title: Indian J Med Res doi: 10.4103/ijmr.IJMR_1409_18 – volume: 113 start-page: 1105 issue: 4 year: 1991 ident: 3231_CR18 publication-title: Development doi: 10.1242/dev.113.4.1105 – volume: 19 start-page: 339 issue: 3 year: 2022 ident: 3231_CR50 publication-title: Cancer Genomics Proteomics doi: 10.21873/cgp.20324 – ident: 3231_CR25 doi: 10.14639/0392-100X-N1527 – volume: 118 start-page: 109384 year: 2019 ident: 3231_CR34 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2019.109384 – volume: 17 start-page: 168 issue: 3 year: 2020 ident: 3231_CR8 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-019-0284-3 – volume: 21 start-page: 628 issue: 3 year: 2017 ident: 3231_CR53 publication-title: Cell Rep doi: 10.1016/j.celrep.2017.09.078 – volume: 80 start-page: 71 issue: 1 year: 2021 ident: 3231_CR30 publication-title: Eur Urol doi: 10.1016/j.eururo.2021.03.005 – volume: 99 start-page: 807 issue: 4 year: 2007 ident: 3231_CR7 publication-title: BJU Int doi: 10.1111/j.1464-410X.2006.06663.x – volume: 35 start-page: 595 issue: 1 year: 2014 ident: 3231_CR10 publication-title: Tumour Biol doi: 10.1007/s13277-013-1083-6 – volume: 8 start-page: e2101895 issue: 20 year: 2021 ident: 3231_CR51 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202101895 – volume: 9 start-page: 15512 issue: 21 year: 2018 ident: 3231_CR23 publication-title: Oncotarget doi: 10.18632/oncotarget.24496 – volume: 33 start-page: 21 issue: 3 year: 2016 ident: 3231_CR52 publication-title: Med Oncol doi: 10.1007/s12032-016-0734-z – volume: 22 start-page: 968 issue: 2 year: 2021 ident: 3231_CR35 publication-title: Int J Mol Sci doi: 10.3390/ijms22020968 – ident: 3231_CR3 doi: 10.1001/jama.294.4.433 – volume: 24 start-page: 505 issue: 8 year: 2020 ident: 3231_CR39 publication-title: Omics – volume: 71 start-page: 209 issue: 3 year: 2021 ident: 3231_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 12 start-page: 2 issue: 1 year: 2021 ident: 3231_CR40 publication-title: Cell Death Dis doi: 10.1038/s41419-020-03354-4 – ident: 3231_CR46 doi: 10.3390/cancers13010015 – volume: 74 start-page: 210 issue: 2 year: 2014 ident: 3231_CR6 publication-title: The Prostate doi: 10.1002/pros.22742 – volume: 10 start-page: 3918 issue: 10 year: 2021 ident: 3231_CR9 publication-title: Transl Androl Urol doi: 10.21037/tau-20-1118 – volume: 43 start-page: 49 issue: 1 year: 1998 ident: 3231_CR20 publication-title: J Hum Genet doi: 10.1007/s100380050036 – volume: 8 start-page: 98 year: 2016 ident: 3231_CR13 publication-title: Clin Epigenetics doi: 10.1186/s13148-016-0264-8 – volume: 500 start-page: 253 year: 2021 ident: 3231_CR26 publication-title: Cancer Lett doi: 10.1016/j.canlet.2020.11.006 – volume: 13 start-page: 418 issue: 4 year: 2021 ident: 3231_CR4 publication-title: Urol Ann doi: 10.4103/UA.UA_47_20 – volume: 281 start-page: 3766 issue: 16 year: 2014 ident: 3231_CR28 publication-title: FEBS J doi: 10.1111/febs.12902 |
| SSID | ssj0017860 |
| Score | 2.3832774 |
| Snippet | Background
About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the... About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of... BackgroundAbout 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the... Abstract Background About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 56 |
| SubjectTerms | Androgens Antibodies Biomedical and Life Sciences Biomedicine Bone growth Cancer Research Cancer therapies Cell adhesion & migration Cell adhesion molecules Cell Biology Cell death Cell proliferation Cytokeratin DNA methylation E-cadherin Epigenetics Estrogens Gene expression Gene regulation Genotype & phenotype Histones Hypoxia Immunodeficiency Immunohistochemistry lncRNA Lysine demethylase Metastases Metastasis Preclinical models Prostate cancer Stem cells Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yIPgiftvzlAi-adg0TdLkUcVzOcEX7-DeQpImbsHrHt0usv-9k7RdXT9ffGyTwnRm0vwmnfkNQi8E57yBDz-RjfcE8K0gSnlLNPc2euuc8DlB9qNcXvCzS3H5Q6uvlBM20gOPiluwEKWrLOBeqbgIzPlEXamVjpW2ZZXLfKmmczA1_T-olaRziYySi03a1VIlMie0AkRD5ME2lNn6fwcxf82U_Ol3ad6FTu-g2xN8xK9Hse-iG6G7h26ODSV399HX85zYDY_idcTLUi_SwTy2zSqkUzF8NTbDDRvs295v26HfYbfD7z99IGcch-u26befcdutWtcOG3wVBpsqjlqPcx7XyOEB4-kylyJhn7ymf4AuTt-dv12SqbUC8RBwDMQ10UYH9ouWW8AgDGCdjoDmYgxShQjqA6QmRVlTz2Joopde0CbUMVXiMlo9REfduguPEQ4pSNFNZEp67jiHDyaAMKEFLQNsfbRA5axp4yfe8dT-4ovJ8YeSZrSOAeuYbB0jC_Ry_8z1yLrx19lvkgH3MxNjdr4BfmQmPzL_8qMCnczmN9My3himWeJP0xyGn--HYQEm49kurLd5DtO8ripdoEejt-wlgfC_rAEiF0gd-NGBqIcjXbvKJN8lBTFrCS_3ana573L9WRfH_0MXT9AtltcKI1ScoKOh34angL0G9ywvs289wymQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dj9QgECd6xsQX47fV02Dim5JtKVB4Mmo8N2fii3fJvhFK4bbJXbu23Zj97x1ou5f14x5bIAFmBn4zzAdCbzljrIKDn4jKWgL4lhMprSGKWeOtKUtuo4Psd7E8Z6crvpoMbv3kVjmfifGgrlobbOQLqmhIZaWY_LD5SULVqPC6OpXQuI3uZABVAlcXq73ClRVSpHOgjBSLPtxtIR6ZkTQHXEPEwWUUc_b_C2j-7S_5x6NpvItOHqD7E4jEH0eqP0S3XPMI3R3LSu4eo19n0b0bhuLW42WmFsE8j021dsE2hq_Gkriux7bu7LYeuh0ud_jrj2_klGG3qatue4HrZl2X9dDjKzeYEHdUWxy9ucZMHtAePmNAEraBd7on6Pzky9nnJZkKLBALasdAysobXwIVvWEGkAgFcKc8YDrvnZDOw_YBXhM8K1JLvau8FZanlSt8iMelaf4UHTVt454j7IKqoipPpbCsZAyOTYBiXPE0c3ABpgnK5p3Wdso-HopgXOqohUihR-pooI6O1NEiQe_2YzZj7o0be38KBNz3DHmz44-2u9CTGGrqvChzA1qUkIw7WtqQCFVJ5XNlslwm6Hgmv56EudfXrJegN_tmEMNAPNO4dhv7UMWKPFcJejZyy34muQSQBkA5QfKAjw6metjS1OuY6jtLYZqFgMW9n1nuel7_34sXNy_jJbpHoxRQkvJjdDR0W_cKsNVQvo4C9Buh5iHw priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWgCIlLRflMKchI3MBq4tiOfYQVZVUkLrRSb5bt2Gwkmq2yWVX77zt2soGFFolj4rHkeGbsN_HMM0LvOGOshoWfiNo5AviWEymdIYo5E5yxlruUIPtNzM_Z6QW_GGlyYi3M7-f3hRTHq7gfxRpiRvISsAgR99EDDgtvTN-bidl0YlBJkW-LYm7tt7PxJH7-20Dl37mRfxyQpn3n5DHaHwEj_jho-ADd8-0T9HC4QnLzFF2fpVRu6IqXAc8LdRx_xWNTL3z8D4Yvh-tv_Qq7pnPrpu822G7wl-9fySnD_qqpu_UP3LSLxjb9Cl_63sQao8bhlLk1sHZAe3xMxUfYRTvpnqHzk89nszkZL1MgDkKMntg6mGBBY8EwA6iDApBTAfBbCF5IH2D6AJsJXlS5o8HXwQnH89pXIdbe0rx8jvbaZetfIuxjWKLqQKVwzDIGSyTALq54XnjY7PIMFduZ1m5kGo8XXvzUKeKQQg_a0aAdnbSjRYbeT32uBp6Nf0p_igqcJCNHdnoBpqNHl9PUB2FLAxGTkIx7al0kPVVShVKZopQZOtqqX4-Ou9JU0ciYphg0v52aweWi8kzrl-skQxWrylJl6MVgLdNIIOAvKgDFGZI7drQz1N2WtlkkWu8ih2FWAj7uw9bkfo3r7rk4_D_xV-gRTV5BSc6P0F7frf1rwFW9fZMc6gbkFhqw priority: 102 providerName: Springer Nature |
| Title | Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer |
| URI | https://link.springer.com/article/10.1186/s12935-024-03231-6 https://www.ncbi.nlm.nih.gov/pubmed/38317193 https://www.proquest.com/docview/2925630948 https://www.proquest.com/docview/2922947339 https://pubmed.ncbi.nlm.nih.gov/PMC10845766 https://doaj.org/article/2ef6b3a5976845e2bc6148989f39a138 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELf2IdBeEN8URmUk3sAscWzHfkCIVhvTEBMaq1TxEjmOvUba0pGmgv73nJ2mo9DxUim1E13uI_c723eH0GvOGCvgw09EYQwBfMuJlEYTxYx2Ruc5N-GA7Kk4HrGTMR9voa7d0ZKBs42hne8nNaov3_36sfgABv8-GLwUBzPvs3yeMSNRAniFiG20C56Jei3_wm52FVLZZg2zlBMqRdol0Wx8xh66C9FbnIY96T98VijtvwmP_nus8q-91eCyju6je0usiT-2yvEAbdnqIbrTdp9cPEI_z8MpcLgVTx0-jtWBX8XHuphYv4SGr9rOuXaGTVmbednUC5wv8Kdvn8kJw_a6LOr5BS6rSZmXzQxf2Ub79KTS4HDoqy34AeP-MuQtYeNVrH6MRkeH58NjsuzDQAxEJw3JC6ddDsJ2mmkALBQwoHIA_ZyzQloHXAVYJ3icRoY6WzgjDI8Kmzqftkuj5AnaqaaVfYaw9RGNKhxw37CcMfi6AmLjikexBT8Z9VDccTozyyLlvlfGZRaCFSmyVlAZCCoLgspED71Z3XPdluj47-yBF-Bqpi-vHf6Y1hfZ0lozap3IEw3BlpCMW5obXy9VSeUSpeNE9tB-J_6sU9mMKuqLrSkGw69Ww2CtXni6stN5mEMVS5NE9dDTVltWlHTa1kNyTY_WSF0fqcpJqAgeR0BmKuDl3nYqd0PX7bx4fisNL9AeDbZAScT30U5Tz-1LQF9N3kfb6Tjto93B4enXM7gaimE_rGT0g7HB79ng-2-GNywr |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJgQviG8CA4wET2A1cRzXfpgQg41uHRWCTtpb5jj2GomlJU019Z_jb-PsJJ3Kx972mNiObN_57nfxfSD0OmGM5SD4Cc-1JoBvEyKEVkQyraxWWZZo7yA74oNjdniSnGygX10sjHOr7GSiF9T5VLt_5D0qqUtlJZl4P_tJXNUod7valdBQbWmFfMenGGsDO4ZmeQEm3Hzn4BPQ-w2l-3vjjwPSVhkgGrB3TbLcKpvBUqxiCtQxBYQjLQAbaw0XxgoeAmjhSdQPNbUmt5rrJMxN37qgVBrG8N0baAtgRwynamt3b_T12-oeow-ju1AdwXtzp11dRDQjYQzIivA1deirBvwL6v7tsfnHta3Xhvt30Z0WxuIPDd_dQxumvI9uNoUtlw_Qxdg7mMNQPLV4EMmeuyDAKp8Y93cOnzdFec0c66LSi6Kuljhb4s_fh-SQYTMr8mpxhotyUmRFPcfnplYu8qnQ2PuTNblEoN09-pAorB33Vg_R8bVs_iO0WU5L8wRh44wlmVsquGYZYyC4AQwmMgkjAyo4DFDU7XSq2_znrgzHj9TbQYKnDXVSoE7qqZPyAL1djZk12T-u7L3rCLjq6TJ3-xfT6ixtBUFKjeVZrMCO44IlhmbapWKVQtpYqigWAdruyJ-24mSeXjJ_gF6tmkEQOOKp0kwXvg-VrB_HMkCPG25ZzSQWABMBqgdIrPHR2lTXW8pi4pONRyFMs89hce86lruc1__34unVy3iJbg3GX47So4PR8Bm6Tf2JoCRMttFmXS3Mc0B6dfaiPU4YnV73Cf4NA3pm4g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgCMTLxOfIGGAk3sBq4jiO_QiFUjY0IbFJe7Mcx14jsbRKU6H-95ydDygMJB4Tn6WL7y7-2b77GaFXGWOshB8_4aUxBPBtRoQwmkhmtDO6KDITEmRP-fycHV9kF79U8Yds9-FIsqtp8CxNdTtZla4LccEnaz9L-cpiRuIUEArhN9Etz9Xl2fOnfDqeI-SCx0OpzLX9dqajwNp_HdT8M2Pyt2PTMBvN7qH9Hkbit53d76Mbtn6AbncXS24fou9nIcEbuuKlw_NETvwGPdblwvrdMXzVXYpr19hUjdlUbbPFxRZ__HpCjhm2q6psNpe4qhdVUbVrfGVb7SuPKoNDPlfH5QHt_jGUJGHjvad5hM5nH86mc9JfsUAMLDxaUpROuwLs6DTTgEUowDvpANU5Z7mwDoYPEBvPkjw21NnSGW6yuLS58xW5NE4fo716WdsnCFu_WJGlo4IbVjAGP04AY5nM4sTCFBhHKBlGWpmef9xfg_FNhXWI4KqzjgLrqGAdxSP0euyz6tg3_in9zhtwlPTM2eHFsrlUfSAqah0vUg3rKC5YZmlhPBWqFNKlUiepiNDRYH7Vh_NaUUk9j5pk0PxybIZA9MbTtV1uggyVLE9TGaGDzltGTVIBMA2gcoTEjh_tqLrbUleLQPadxKBmzuHj3gwu91Ovv4_F4f-Jv0B3vryfqc-fTk-eors0BAglcXaE9tpmY58B8GqL5yG2fgC6viXv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+of+H19%2Fcell+adhesion+molecules+circuitry+by+GSK-J4+epidrug+inhibits+metastatic+progression+in+prostate+cancer&rft.jtitle=Cancer+cell+international&rft.au=Pecci%2C+Valeria&rft.au=Troisi%2C+Fabiola&rft.au=Aiello%2C+Aurora&rft.au=De+Martino%2C+Sara&rft.date=2024-02-05&rft.issn=1475-2867&rft.eissn=1475-2867&rft.volume=24&rft.issue=1&rft.spage=56&rft_id=info:doi/10.1186%2Fs12935-024-03231-6&rft_id=info%3Apmid%2F38317193&rft.externalDocID=38317193 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon |